The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts – members of the Neuraminidase Inhibitor Susceptibility Network – on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapyare pleased to be able to provide this document in an expeditious manner.
References
1.
ZambonM., HaydenF.G.; Global Neuraminidase Inhibitor Susceptibility Network. Position statement: global neuraminidase inhibitor susceptibility network.Antiviral Research2001; 49: 147–156.
2.
BrightR.A., MedinaM.J., XuX., Perez-OronozG., WallisT.R., DavisX.M., PovinelliL., CoxN.J., & KlimovA.I.Incidence of amantadine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.The Lancet2005; 366: 1175–1181.
de JongM., ThanhT.T., KhanhT.H., HienV., SmithG., ChauN.V., CamB.V., QuiP.T., HaD.Q., GuanY., PeirisJ.S.M., HienT.T., & FarrarJ.Oseltamivir resistance during treatment of influenza H5N1.New England Journal of Medicine2005; 353: 25–30.
5.
PeirisJ.S., YuW.C., LeungC.W., CheungC.Y., NgW.F., NichollsJ.M., NgT.K., ChanK.H., LaiS.T., LimW.L., YuenK.Y., & GuanY.Re-emergence of fatal human influenza A subtype H5N1 disease.The Lancet2004; 363: 617–619.
6.
HienT.T., LiemN.T., DungN.T., SanL.T., MaiP.P., ChauN.V., SuuP.T., DongV.C., MaiL.T.Q., ThiN.T., KhoaD.B., PhatL.P., TruongN.T., LongH.T., TungC.V., GiangL.T., ThoN.D., NgaL.H., TienN.T.K., SanL.H., TuanL.V., DolecekC., ThanhT.T., de JongM., SchultszC., ChengP., LimW., HorbyP. the World Health Organization International Avian Influenza Investigative Team & Farrar J. Avian influenza A (H5N1) in 10 patients in Vietnam.New England Journal of Medicine2004; 350: 1179–1188.
7.
IlyushinaN.A., GovorkovaE.A., & WebsterR.G.Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia.Virology2005; 341: 102–106.
8.
NISN.NISN statement on antiviral resistance in influenza viruses.Weekly Epidemiological Record2004; 79: 306–308.
9.
NISN.Use of influenza antivirals during 2003–2004 and monitoring of neuraminidase inhibitor resistance.Weekly Epidemiological Record2005; 80: 156.
10.
HaydenF.G.Perspectives on antiviral use during pandemic influenza.Philosophical Transactions of the Royal Society of London2001; 356: 1877–1884.
11.
LenevaI.A., RobertsN., GovorkovaE.A., GoloubevaO.G., & WebsterR.G.The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.Antiviral Research2000; 48: 101–115.
12.
GovorkovaE.A., FangH.B., TanM., & WebsterR.G.Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.Antimicrobial Agents and Chemotherapy2004; 48: 4855–4863.
13.
IsonM.G., GnannJ.W.Jr., Nagy-AgrenS., TreannorJ., PayaC., SteigbigelR., ElliottM., WeissH.L., HaydenF.G.; NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza.Antivir Therapy2003; 8: 183–190.
MedinaM., BrightR.A., XuX., CoxN., & KlimovA.I.Susceptibility of influenza A(H5N1) and H3N2 viruses isolated over the last three yers to neuraminidase inhibitors.Second European Influenza Conference. 11–14 September 2005, St Julian's, Malta. Abstract 62.
16.
IvesJ.A., CarrJ.A., MendelD.B., TaiC.Y., LambkinR., KellyL., OxfordJ.S., HaydenF.G., & RobertsN.A.The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.Antiviral Research2002; 55: 307–317.
17.
YenH.L., HerlocherL.M., HoffmannE., MatrosovichM.N., MontoA.S., WebsterR.G., GovorkovaE.A.Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.Antimicrobial Agents & Chemotherapy2005; 49: 4075–4084.
18.
WardP., SmallI., SmithJ., SuterP., & DutkowskiR.Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic.The Journal of Antimicrobial Chemotherapy2005; 55 (Suppl 1): i5–21.
19.
KisoM., MitamuraK., Sakai-TagawaY., ShiraishiK., KawakamiC., KimuraK., HaydenF.G., SugayaN., & KawaokaY.Resistant influenza A viruses in children treated with oseltamivir: descriptive study.The Lancet2004; 364: 759–765.
The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza. Avian influenza A (H5N1) infection in humans.The New England Journal of Medicine2005; 353: 1374–1385.
22.
JacksonH.C., RobertsN., WangZ., & BelsheR.Management of influenza: Use of new antivirals and resistance in perspective.Clinical Drug Investigations2000; 20: 447–454.
23.
GubarevaL.V., KaiserL., MatrosovichM.N., Soo-HooY., & HaydenF.G.Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.Journal of Infectious Diseases2001; 183: 523–531.
24.
YenH.L., MontoA.S., WebsterR.G., & GovorkovaE.A.Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice.Journal of Infectious Diseases2005; 192: 665–672.
25.
McKimm-BreschkinJ., TrivediT., HampsonA., HayA., KlimovA., TashiroM., HaydenF., & ZambonM.Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.Antimicrobial Agents & Chemotherapy2003; 47: 2264–2272.7.
26.
MishinV.P., HaydenF.G., & GubarevaL.V.Susceptibilities of Antiviral-resistant influenza viruses to novel neuraminidase inhibitors.Antimicrobial Agents and Chemotherapy2005; 49: 4515–4520.
